Barrington analyst Michael Petusky raised the firm’s price target on Option Care Health (OPCH) to $42 from $38 and keeps an Outperform rating on the shares after the company announced preliminary Q4 results and disclosed some aspects of its expectations for FY26. While modeling “solidly within” the company’s guidance ranges, Option Care has a history of “beat and raise” results, says the analyst, who thinks there is some upside to management’s FY26 guidance.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health: Resilient Core Growth, Structural Tailwinds, and Capital Allocation Support Buy Rating
- Option Care Health price target raised to $38 from $36 at Citizens
- Closing Bell Movers: Revvity up 9% on strong outlook
- Option Care Health Issues 2025 Results and 2026 Outlook
- Option Care Health raises FY25 adjusted EPS view to $1.72-$1.76 from $1.68-$1.72
